Lantern Pharma Inc. (LTRN) Q4 2025 Earnings Call Prepared Remarks Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture. While the company is making progress in product development and AI expansion, it faces significant risks, including funding challenges and competitive pressures. Financial metrics show reduced losses, but the need for additional funding and operational risks dampen enthusiasm. The absence of shareholder return discussions and unclear management responses in the Q&A further contribute to a neutral sentiment.
Key Financial Performance
General and Administrative Expenses (Q4 2025) $1.5 million, a decrease from $1.6 million in the prior year period. The reduction was not explicitly attributed to specific reasons.
R&D Expenses (Q4 2025) $2.7 million, a decrease from $4.3 million in Q4 2024. The reduction was primarily due to a decrease in research studies and materials related to clinical trials.
Net Loss (Q4 2025) $4.1 million or $0.36 per share, a decrease from $5.9 million or $0.54 per share in Q4 2024. The reduction was due to lower R&D expenses.
R&D Expenses (Full Year 2025) $11.5 million, a decrease from $16.1 million in 2024. The reduction was primarily due to a $4 million decrease in research studies and materials, a $0.6 million decrease in payroll and compensation expenses, and an $81,000 decrease in consulting expenses.
General and Administrative Expenses (Full Year 2025) $6.5 million, an increase from $6.1 million in 2024. The increase was due to higher business development and investor relations expenditures ($436,000), patent costs ($55,000), and corporate insurance ($51,000).
Net Loss (Full Year 2025) $17.1 million or $1.57 per share, a decrease from $20.8 million or $1.93 per share in 2024. The reduction was primarily due to lower R&D expenses.
Cash Position (End of 2025) $10.1 million, sufficient to fund operations until late July 2026 to mid-September 2026. No specific reasons for the cash position were provided.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
LP-300 Program: Advanced Phase II HARMONIC trial for non-small cell lung cancer in never smokers. Demonstrated 86% clinical benefit rate and 43% objective response rate. FDA Type C meeting scheduled for mid-May 2026 to discuss protocol amendments.
LP-184 Program: Reported positive Phase I results with a 48% clinical benefit rate. Planning Phase Ib/II trials in triple-negative breast cancer, non-small cell lung cancer, and bladder cancer. Demonstrated potential in transforming immunologically cold tumors into hot tumors.
Starlight Therapeutics: Cleared IND for pediatric CNS cancer trial. Received rare pediatric disease and orphan drug designations for multiple cancers. Demonstrated unique combination therapy with spironolactone for brain tumors.
LP-284 Program: Received FDA orphan drug designation for soft tissue sarcoma. Demonstrated complete metabolic response in diffuse large B-cell lymphoma patient.
AI Center of Excellence in India: Established to expand RADR platform's commercial reach and revenue potential globally.
withZeta.ai Platform: Launched multi-agentic AI platform for drug discovery. Beta tested with over 25 biotech companies and research centers. Plans for multi-tiered commercial architecture.
Cost Reduction: Achieved 19% reduction in total operating expenses year-over-year.
Funding and Financials: Cash position of $10.1 million as of December 31, 2025. Actively pursuing additional funding to support operations and clinical advancements.
AI-Driven Drug Development: Focused on integrating AI and machine learning to accelerate drug discovery and development.
Partnerships and Collaborations: Exploring global collaborations for LP-300 and other programs. Actively seeking partners for LP-284 and other assets.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Clinical Trial Risks: The company faces risks related to clinical trials, including the need for additional funding to initiate and continue trials, challenges in patient enrollment, and evolving treatment landscapes that may require changes in trial design.
Regulatory Risks: The company is dependent on FDA feedback and approvals for its drug candidates, which could delay or impact the progress of its clinical programs.
Funding Challenges: Lantern Pharma requires substantial additional funding to sustain operations and advance clinical trials, with current cash reserves projected to last only until late July to mid-September 2026.
Competitive Pressures: The company operates in a highly competitive market, particularly in AI-driven drug discovery and oncology, which could impact its ability to secure partnerships and commercialize its platforms and therapies.
Market Adoption Risks: The success of the company's AI-driven platforms and therapies depends on market adoption, which may be hindered by skepticism or resistance to new technologies in drug development.
Operational Risks: The company faces operational risks, including the need to scale its AI platform and recruit specialized talent, particularly for its new AI center of excellence in India.
Reputation Risks: The company has been impacted by malicious and false information, which has harmed its reputation and stock price, potentially affecting investor confidence.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Advancement of Clinical Programs: Lantern Pharma plans to advance its clinical programs, including LP-300, LP-184, and STAR-001, into further trials in 2026. This includes a Type C meeting with the FDA for LP-300 to discuss protocol amendments and focusing on specific patient populations for better outcomes.
Expansion of AI Platform: The company aims to expand the commercial reach and revenue potential of its RADR AI platform globally, including the establishment of an AI center of excellence in India. This expansion is expected to enhance scalability and support additional biopharma partnerships.
Market Potential: Lantern Pharma's AI-driven clinical pipeline targets a combined estimated annual market potential exceeding $15 billion, approaching $20 billion, across solid tumors, blood cancers, and pediatric oncology.
Future Trials and Partnerships: Planned trials include LP-184 in triple-negative breast cancer, non-small cell lung cancer, and bladder cancer, subject to funding. The company is actively exploring global collaboration and partnering opportunities to maximize the commercial potential of its treatments.
Starlight Therapeutics Development: Starlight Therapeutics, a subsidiary, is positioned to move into clinical trials for pediatric CNS cancers, leveraging FDA IND clearance and rare pediatric disease designations. This includes potential FDA priority review vouchers valued at $150-$200 million each.
Commercialization of withZeta Platform: Lantern Pharma plans to launch its withZeta multi-agentic AI platform commercially, targeting a broader market opportunity of $20-$50 billion. The platform is designed for drug discovery and scientific R&D, with a multi-tiered subscription model.
Funding Requirements: The company anticipates the need for substantial additional funding to support its operations and clinical advancements, with current cash reserves expected to last until late July to mid-September 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI center
AI drug
AI technology
CD
EGFR exon
ERCC
IND
PRVs
Phase II
RADR AI
RADR platform
STAR
Type meeting
afternoon
architecture
arm
chemo
class
concept
control
drug designation
exon LR
experiment
feature
hypothesis
idea
immunotherapy
increase
knowledge
lethality
oncology trial
orphan drug
protein
reduction
spironolactone
standard
treatment cycle
week
withZeta
withZetaai
LTRN Transcript
Lantern Pharma Inc. (LTRN) Q4 2025 Earnings Call Prepared Remarks Transcript
Unknown3-30
The earnings call presents a mixed picture. While the company is making progress in product development and AI expansion, it faces significant risks, including funding challenges and competitive pressures. Financial metrics show reduced losses, but the need for additional funding and operational risks dampen enthusiasm. The absence of shareholder return discussions and unclear management responses in the Q&A further contribute to a neutral sentiment.
Lantern Pharma Inc. (LTRN) Q3 2025 Earnings Call Transcript
Positive11-13
The earnings call indicates a positive sentiment due to the commercialization of the RADR AI platform with high predictive success, optimistic financial guidance, and strategic advancements like the withZeta AI system. Despite challenges in market conditions and regulatory hurdles, the company shows resilience with strategic execution and competitive positioning. The Q&A session provided clarity and positive updates, particularly on trials and AI platform rollout. The decrease in R&D expenses and slight improvement in net loss also contribute to a positive outlook, warranting a 'Positive' rating for the stock price movement.
Lantern Pharma Inc. (NASDAQ:LTRN) Q1 2025 Earnings Call Transcript
Unknown5-16
The earnings call presents a mixed picture. The company beat EPS expectations, which is positive, but lacks clarity on shareholder returns and specific strategic details. The AI platform expansion and clinical trial progress are promising, yet the market faces risks from competition and regulatory issues. The Q&A session revealed some uncertainty about AI integration timelines and FDA processes. Without a clear market cap and given the absence of strong catalysts or new partnerships, the stock is likely to remain neutral in the short term.
Lantern Pharma Inc. (LTRN) Q1 2025 Earnings Call Transcript
Unknown5-15
The earnings call presents a mix of positive and negative elements. Financial performance shows a decrease in net loss and R&D expenses, but the need for additional funding is a concern. Product development and market potential are promising, but competition and regulatory risks persist. The Q&A section revealed some uncertainties, particularly around AI platform commercialization and funding. Positive aspects like geographic expansion and AI advancements are balanced by risks and funding needs, leading to a neutral sentiment. Without market cap information, the impact on stock price remains uncertain, suggesting a neutral prediction.
LTRN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
